
Search
Filter Results
Displaying 311–320 of 1070 results
-
Jan 25, 2023
Foundation Fighting Blindness to Host PRPH2 and Associated Retinal Diseases Workshop
Session to have special translational research emphasis on PRPH2 and inherited macular dystrophies.
-
Mutations in PRPH2 are a relatively common cause of several inherited retinal degenerations, including: retinitis pigmentosa (RP), pattern macular dystrophies (PMDs), cone-rod dystrophies (CRDs), and central areolar choroidal dystrophy (CACD).
-
Jan 23, 2023
Birding Blind: Identifying Birds by Song
Martha Steele has been birding for over 30 years, but the way in which she birds has changed over time. Martha has Usher syndrome, with her central vision declining rapidly in the early 2000s and receiving her first cochlear implant in 2010. Now she birds entirely by ear and has learned the songs of about 150 bird species.
-
Jan 20, 2023
Eye on the Cure Podcast | Episode 39: Paul Bernstein, MD, PhD
January 20, 2023. Paul Bernstein, MD, PhD, from the Moran Eye Center, University of Utah, and a member of the Foundation’s Scientific Advisory Board talks to host Ben Shaberman about his clinical practice for retinal disease patients
-
Jan 9, 2023
Retinal Research Community Loses Beloved Pioneer Sam Jacobson
His many contributions included pivotal work that led to LUXTURNA
-
Jan 9, 2023
Fearless Sister Duo Finding Hope
April LuFriu and Melissa Escobio are sisters and best friends who do just about everything together, including having retinitis pigmentosa (RP).
-
Jan 6, 2023
Eye on the Cure Podcast | Episode 38: Ben Shaberman
January 6, 2023. For the first Eye on the Cure episode for 2023, host Ben Shaberman highlights some of the promising clinical advancement made in therapy development over the last year.
-
Jan 6, 2023
The Retinal Degeneration Fund invests in a $78M Series B for Perceive Biotherapeutics
The investment supports the clinical development of two novel programs, both with the aim of being protective against vision loss.
-
Jan 3, 2023
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
The company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
A variety of resources for your endurance fundraising activities.